Insight

Shilpa Gupta: Happy to share our comprehensive review on adjuvant treatment of muscle-invasive urothelial cancer

Photo of Shilpa Gupta taken from X/Twitter

Apr 8, 2024, 15:36

Shilpa Gupta: Happy to share our comprehensive review on adjuvant treatment of muscle-invasive urothelial cancer

Shilpa Gupta, Director of Genitourinary Oncology at Cleveland Clinic, shared on LinkedIn:

“Happy to share our comprehensive review on adjuvant treatment of muscle-invasive urothelial cancer!
A lot of progress has been made in MIBC with promising signals with ICI. (Checkmate 274, AMBASSADOR)
ctDNA appears to be a robust biomarker for patient selection. (IMvigor010)
Ongoing trial utilizing ctDNA for patient election will help advance the field further. (IMvigor011 and MODERN)
ICI not shown benefit in adjuvant UTUC, platinums remain kingpin.
Unmet need to learn from precision-oncology trials like PROOF302 (in FGFR3 select tumors).”

graphical user interface, text, application

Source: Shilpa Gupta/LinkedIn

adjuvant treatment AMBASSADOR trial cancer Checkmate 274 trial Cleveland Clinic ICI treatment immune checkpoint inhibition IMvigor010 trial IMvigor011 trial MIBC MODERN trial muscle-invasive urothelial cancer OncoDaily Oncology PROOF302 trial Shilpa Gupta upper tract urothelial cancer urothelial cancer

Top 100 Xfluencers in Lung Cancer: Key Opinion Leaders to Follow on X (Twitter) in 2024

100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2024: Part 10

OncoThon 2024 Raises $1.3 Million for Pediatric Cancer Research

Richard Sullivan: Do we need a 'new' Geneva Convention and protocols?

Remembering Virgil Abloh: Louis Vuitton’s Creative Director Honored at 41 After His Brave Battle with Cardiac Angiosarcoma

Special Coverage